phase 2_completion
saveBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)
community read0 votes
Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis
Data sources
globaldata
Found something off?
drug timeline · 8
- pdufaRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)Apr 27, 2026 · 163d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2026 · 174d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalFeb 23, 2026 · 226d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalJun 18, 2025 · 476d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 17, 2025 · 538d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2025 · 539d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 27, 2024 · 740d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 12, 2024 · 755d ago
same company · ±60 days · 6
- grantBRIGHAM AND WOMEN'S HOSPITAL — Macrophage-directed strategies for BRCA-associated breast cancerApr 10, 2026
- grantBRIGHAM AND WOMEN'S HOSPITAL — Lipidomic discovery of physiological CD1 antigens and blockers for human T cellsApr 9, 2026
- grantBRIGHAM AND WOMEN'S HOSPITAL — Immune regulatory role of reactive oxygen species (ROS) in sepsisApr 6, 2026
- grantBRIGHAM AND WOMEN'S HOSPITAL — Integrative Single-Cell Analysis of Aging-Associated Changes in Human Hematop...Apr 1, 2026
- grantBRIGHAM AND WOMEN'S HOSPITAL — Early Immune Signatures of COPD: Linking Inflammation to Disease ProgressionApr 1, 2026
- grantBRIGHAM AND WOMEN'S HOSPITAL — miR-10b Gene Editing Therapy for GlioblastomaApr 1, 2026
comments(0)
5-min edit window · permanent after that